The Cellular, Tissue and Gene Therapies Advisory Committee — formerly called the Biological Response Modifiers Advisory Committee — reviews and evaluates available data relating to the safety, effectiveness, and appropriate use of human cells, human tissues, gene transfer therapies, and xenotransplantation products that are intended for transplantation, implantation, infusion, and transfer in the prevention and treatment of a broad spectrum of human diseases and in the reconstruction, repair or replacement of tissues for various conditions. Members of the committee include authorities knowledgeable in the fields of cellular therapies, tissue transplantation, hematology/oncology, and human tissues and transplantation, among other specialties.
Cell Notes: Looking Back, Moving Forward: Exciting New Developments in Biotherapies
December 18, 2024
FDA Workshop to Focus on Generating Scientific Evidence to Facilitate CT Development
December 18, 2024
Advanced Therapies Week: AABB to Host Fireside Chat on Sustainable Donor Sourcing
December 13, 2024